Biogen Hirulog licensed to The Medicines Company for $30 mil..

BIOGEN LICENSES HIRULOG TO THE MEDICINES COMPANY FOR $30 MIL. in upfront fees, milestone payments and development commitments, plus royalties on Hirulog sales, The Medicines Company announced March 25. Cambridge, Mass.-based TMC notes that its "deal structures are arranged to include royalties and milestone payments to the originating pharmaceutical company if market performance of a product exceeds the expectation of both parties." In return, TMC holds exclusive worldwide rights to develop and sell the synthetic leech protein derivative Hirulog (bivalirudin).